Pacific Biosciences of California Q3 2026 Results: Net Loss of $37.8M, Loss Narrows
Pacific Biosciences reported total revenue of $40.6 million for Q3 2026, a slight increase from $38.4 million in the prior year. The company recorded a net loss of $37.8 million for the quarter, showing improvement over the $506.0 million net loss in the nine-month period of 2025 which was heavily impacted by significant intangible asset amortization and impairment charges.
- Key figure
- Net loss $37.8M